pravastatin has been researched along with Diabetes Mellitus, Type 2 in 100 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.00) | 18.7374 |
| 1990's | 26 (26.00) | 18.2507 |
| 2000's | 48 (48.00) | 29.6817 |
| 2010's | 22 (22.00) | 24.3611 |
| 2020's | 3 (3.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aiello, R; Ammirati, M; Aspnes, G; Atkinson, K; Baker, L; Barucci, N; Bian, J; Bourassa, P; Bourbonais, F; Cabrera, O; Chen, J; D'Aquila, T; Dasilva-Jardine, P; Derksen, DR; Duignan, DB; El-Kattan, A; Feng, B; Filipski, KJ; Guzman-Perez, A; Haddish-Berhane, N; Jones, CS; Knafels, J; Kosa, RE; Landro, JA; Lapworth, AL; Liras, S; Litchfield, J; Liu, S; Macdougall, M; Minich, ML; Murdande, S; Pettersen, J; Pfefferkorn, JA; Risley, H; Robertson, AS; Rolph, TP; Stevens, BD; Sweet, L; Tan, B; Treadway, JL; Tu, M; Varma, MV; Yao, L; Zavadoski, WJ | 1 |
| Jang, H; Jang, WI; Kim, H; Kim, JM; Kim, S; Lee, SB; Oh, SH; Park, M; Park, S; Shim, S | 1 |
| Liu, L; Su, R; Wen, T; Xiao, Z; Xie, Y; Xu, J; Zhang, M; Zhu, L | 1 |
| Chen, WM; Shia, BC; Wu, SY; Yu, JM | 1 |
| Hori, E; Imaeda, K; Kikuchi, C; Matsunaga, T; Okayama, N; Suzuki, T | 1 |
| Betteridge, DJ; Carmena, R | 1 |
| Chang, SA; Kim, JH; Lee, JM; Lee, MR; Lee, SS; Shin, JA; Yoon, KH; You, SJ | 1 |
| Nakagami, T; Nishimura, R; Sone, H; Tajima, N | 1 |
| Camacho, X; Carter, AA; Gomes, T; Juurlink, DN; Mamdani, MM; Shah, BR | 1 |
| Choi, H; Han, SH; Koh, KK; Lee, K; Lee, Y; Lim, S; Oh, PC; Quon, MJ; Sakuma, I; Shin, EK | 1 |
| Macchi, C; Magni, P; Morlotti, B; Ruscica, M; Sirtori, CR | 1 |
| Hori, E; Itoh, T; Kajikuri, J; Kikuchi, C; Kimura, K; Matsunaga, T; Nagami, C | 1 |
| Allen, J; Bibeau, KB; Gooden, KM; Heim, JM; Irizarry, MC; Pan, X; Sampson, T; Wood, J | 1 |
| Li, L; Li, Y; Shen, J; Shen, Y; Su, F; Zhang, D; Zhang, M | 1 |
| Kadonosono, K; Takano, T; Tanaka, S; Terauchi, Y; Yamakawa, T | 1 |
| Horiuchi, M; Inaba, S; Iwai, M; Kanno, H; Mogi, M; Nakaoka, H; Senba, I; Sone, H | 1 |
| Ito, R; Ito, Y; Itoh, T; Kajikuri, J; Watanabe, Y; Yamamoto, T | 1 |
| Charles, MA; Ishida, B; Kane, JP; Malloy, MJ; Pan, J; Shilian, P; Wu, X | 1 |
| Blauw, GJ; Bollen, EL; de Craen, AJ; de Roos, A; Jukema, JW; Middelkoop, HA; van Buchem, MA; van der Grond, J; van Elderen, SG; Westendorp, RG | 1 |
| Bailey, C; Capps, N; Ramachandran, S; Saraf, S; Shetty, C | 1 |
| Koh, KK; Quon, MJ; Sakuma, I | 1 |
| Kadonosono, K; Kaneko, T; Kawaguchi, J; Morita, S; Shigematu, E; Terauchi, Y; Yamakawa, T | 1 |
| Császár, A; Farnier, M; Retterstøl, K; Steinmetz, A | 2 |
| Ishida, K; Kamata, K; Kobayashi, T; Matsumoto, T; Taguchi, K | 1 |
| Inoguchi, T; Kimura, S; Maeda, Y; Sonoda, N; Takayanagi, R; Yokomizo, H | 1 |
| Kamata, K; Kobayashi, T; Matsumoto, T; Nemoto, S; Taguchi, K | 1 |
| Fenger, M | 1 |
| Noda, M | 1 |
| Hosoi, T; Ito, H; Kazama, H; Okazaki, M; Orimo, H; Usui, S | 1 |
| Faust, M | 1 |
| Brandle, M; Davidson, MB; Herman, WH; Lorber, B; Schriger, DL | 1 |
| Arulchelvam, M; Baker, J; Beller, E; Best, J; Colquhoun, D; Hague, W; Hunt, D; Keech, A; Kirby, A; Simes, RJ; Tonkin, A | 1 |
| MacGillavry, MR; Meijers, JC; Reitsma, PH; Sommeijer, DW; Ten Cate, H; Van Zanten, AP | 1 |
| Barter, PJ; Bonnet, J; Cheung, RC; Kallend, D; Morrell, JM; Raza, A; Schuster, H; Stender, S; Watkins, C | 1 |
| Chen, Y; Kiyomoto, H; Kohno, M; Mizushige, K; Ohmori, K; Sato, C; Shinomiya, K; Takeuchi, H; Yu, Y | 1 |
| Buchholz, K; Fliser, D; Haller, H | 1 |
| Güçlü, F; Hekimsoy, Z; Kirmaz, C; Ozmen, B | 1 |
| Endo, K; Ito, Y; Koide, N; Miyashita, Y; Otsuka, M; Oyama, T; Ozaki, H; Saiki, A; Shirai, K | 1 |
| Kawamori, R; Miwa, S; Nishiyama, K; Omura, C; Onuma, T; Takayanagi, N; Tanaka, Y; Watada, H | 1 |
| Joop, K; Leyte, A; Reitsma, PH; Sommeijer, DW; ten Cate, H | 1 |
| Hirose, T; Kawamori, R; Ohmura, C; Tanaka, Y; Watada, H | 1 |
| Goto, R; Higashi, K; Ishii, N; Itai, K; Kobori, S; Takahashi, T | 1 |
| Matsui, T; Sato, T; Takeuchi, M; Yamagishi, S | 1 |
| Gao, L; Ge, JB; Xu, B; Yao, K | 1 |
| Craven, T; Curhan, G; Furberg, C; Isles, C; Keech, A; Packard, C; Pfeffer, M; Sacks, F; Shepherd, J; Simes, J; Tonelli, M; Tonkin, A; West, M | 1 |
| Písaríková, A; Stanková, B; Tvrzická, E; Vecka, M; Zák, A; Zeman, M | 1 |
| Barrett, PH; Chan, DC; Ching, HL; Martins, IJ; Ng, TW; Redgrave, TG; Sakai, N; Stuckey, BG; Uchida, Y; Watts, GF; Yamashita, S | 1 |
| Kimura, M; Okamura, A; Takahashi, M; Takano, T; Yamakawa, T | 1 |
| Huang, Z; Jansson, L; Sjöholm, A | 2 |
| Caixàs, A; Giménez-Palop, O; Giménez-Pérez, G; González-Clemente, JM; Vilardell, C | 1 |
| Vos, E | 1 |
| Kadonosono, K; Okamura, A; Takano, T; Utsunomiya, H; Yamakawa, T | 1 |
| Chen, Y; Kohno, M; Kosaka, H; Mizukawa, M; Ohmori, K; Shinomiya, K; Yoshida, J; Zeng, Y; Zhang, L | 1 |
| Abe, M; Hirose, T; Kawamori, R; Mita, T; Nakayama, S; Ogihara, T; Shimizu, T; Uchino, H; Watada, H | 1 |
| Adachi, M; Hayashi, T; Hirano, T; Ito, Y; Mori, Y; Nagashima, M; Shiraishi, Y; Tokuno, A; Yamamoto, T | 1 |
| Charbonnel, B; Dormandy, J; Erdmann, E; Massi-Benedetti, M; Wilcox, R | 1 |
| Fujita, H; Ito, S; Kakei, M; Koshimura, J; Miura, T; Morii, T; Narita, T; Sasaki, H; Sato, T; Yamada, Y | 1 |
| Doney, AS; Donnan, PT; Donnelly, LA; Lang, CC; Morris, AD; Palmer, CN; Whitley, AL | 1 |
| Blauw, GJ; Buckley, BM; de Craen, AJ; Ford, I; Forouhi, NG; Freeman, DJ; Jukema, JW; Lennon, L; Macfarlane, PW; McConnachie, A; Murphy, MB; Packard, CJ; Sattar, N; Shaper, AG; Shepherd, J; Stott, DJ; Wannamethee, SG; Westendorp, RG; Whincup, PH | 1 |
| Cressman, MD; Ganda, OP; Lodewick, PA; McGovern, ME; Phillipson, B; Raskin, P; Rosenstock, J; Schwartz, S; Weiner, B; Willard, D | 1 |
| Balestrieri, GP; Cerudelli, B; Giustina, G; Marocolo, D; Scalvini, T; Sleiman, I | 1 |
| Cooper, ME; Jerums, G; Panagiotopoulos, S; Sinha, A; Tsalamandris, C | 1 |
| Deerochanawong, C; Serirat, S | 1 |
| Miwa, I; Onaya, T; Ozawa, M; Shindo, H; Tawata, M; Tsuchiya, K; Wakasugi, M | 1 |
| Bhatnagar, D; Boulton, AJ; Dean, J; Durrington, PN; Kumar, S; Mackness, MI | 1 |
| Ishida, Y; Iwatani, I; Kasuga, M; Kazumi, T; Morita, S; Tateiwa, M; Yoshino, G | 1 |
| Akabane, S; Inoue, I; Ishii, J; Katayama, S; Kawazu, S; Negishi, K; Suzuki, M; Takahashi, K | 1 |
| Ando, S; Fujii, S; Hatao, K; Hatao, M; Inoue, Y; Kaku, K; Kaneko, T; Matsumura, S; Okubo, M | 1 |
| Behounek, BD; Bergman, M; Kassler-Taub, KB; Markowitz, JS; McGovern, ME | 1 |
| Hiramatsu, S; Kobayashi, K; Masakado, M; Mimura, K; Nakashima, N; Nawata, H; Umeda, F; Watanabe, J; Yamauchi, T | 1 |
| Ikeda, T | 1 |
| Gylling, H; Miettinen, TA | 1 |
| Leelawattana, R; Rattarasarn, C; Soonthornpun, S; Thamprasit, A | 1 |
| Amelineau, E; Berthezène, F; Desriac, I; Krempf, M; Moinade, S; Passa, P; Wemeau, JL | 1 |
| Fonseca, VA; Gardner, SF; Granberry, MC; Marx, MA; Skelton, DR; White, LM | 1 |
| Janssens, EN; Rustemeijer, C; Schouten, JA; Spooren, PF; van Doormaal, JJ | 1 |
| Chiba, T; Fukuda, M; Nagakubo, H; Ogawa, S; Oouchi, M; Sato, C; Sato, T; Sugimura, K | 1 |
| Hamazaki, T; Jokaji, H; Kobayashi, M; Minami, S; Nakamura, N | 1 |
| Coronado, M; Escola, JM; Robles, NR; Ruiz-Calero, R; Sánchez Casado, E | 1 |
| Harada, N; Kashiwagi, A; Kikkawa, R; Nishio, Y | 1 |
| Hayakawa, T; Inada, M; Miyake, Y; Nishikawa, M; Omoto, S; Shimizu, H; Shouzu, A; Yonemoto, T | 1 |
| David-Dufilho, M; Devynck, MA; Miossec, P; Pariès, J; Valensi, PE; Zkhiri, F | 1 |
| Gotto, AM | 1 |
| Diamond, RH; Forman, LM; Simmons, DA | 1 |
| Chisholm, DJ; Greenfield, JR | 1 |
| Durrington, P | 1 |
| Haffner, SM | 1 |
| Agrusta, M; Amodio, M; Corigliano, G; De Simone, G; Gaeta, I; Gentile, S; Guarino, G; Magliano, P; Oliviero, B; Salvatore, T; Sasso, CF; Torella, R; Turco, S | 1 |
| Beynen, AC; Donker, AJ; Heine, RJ; Rustemeijer, C; Schouten, JA; Voerman, HJ | 1 |
| Mori, M; Nagai, T; Nakajima, K; Tomizawa, T | 1 |
| Faust, M; Kotzka, J; Krone, W; Müller-Wieland, D | 1 |
| Adachi, M; Hirano, T; Katagiri, T; Koba, S; Sakai, K; Sakaue, T; Yoshino, G | 1 |
| Alaupovic, P; Collet, JP; Harvey, L; Leiter, L; McQueen, MJ; Schweitzer, M; Tessier, D; Vlahos, WD | 1 |
| Cantral, KA; Jungnickel, PW; Maloley, PA | 1 |
| Hisatomi, A; Inoue, K; Kunisaki, M; Mimura, K; Nawata, H; Sako, Y; Tajiri, Y; Umeda, F; Watanabe, J; Yamauchi, T | 1 |
| Baba, S; Iwai, M; Iwatani, I; Kazumi, T; Matsuba, K; Matsushita, M; Uenoyama, R; Yoshino, G | 1 |
7 review(s) available for pravastatin and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Diabetogenic Action of Statins: Mechanisms.
Topics: Aged; Animals; Blood Glucose; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Insulin; Male; Metabolic Syndrome; Mice; Middle Aged; Pravastatin; Quinolines; Risk Factors | 2019 |
Statin therapy and related risk of new-onset type 2 diabetes mellitus.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin; Primary Prevention; Risk Assessment; Risk Factors; Secondary Prevention | 2014 |
Differential metabolic effects of distinct statins.
Topics: Adiponectin; Animals; Atorvastatin; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fluorobenzenes; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Mice; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
[Primary prevention of diabetes mellitus by pharmacological intervention].
Topics: Acarbose; Angiotensin-Converting Enzyme Inhibitors; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lactones; Metformin; Orlistat; Pravastatin; Primary Prevention; Ramipril; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Pravastatin; Risk Factors; Simvastatin; Thiazolidinediones; Treatment Outcome; Triglycerides | 2007 |
[Cholesterin synthase inhibition and atherosclerosis].
Topics: Animals; Arteriosclerosis; Cardiovascular Diseases; CCAAT-Enhancer-Binding Proteins; Cholesterol; Cholesterol, LDL; Coenzyme A Ligases; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA Synthase; Hyperlipidemias; Pravastatin; Pyridines; Randomized Controlled Trials as Topic; Sterol Regulatory Element Binding Protein 1; Transcription Factors | 2001 |
Pravastatin: a new drug for the treatment of hypercholesterolemia.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Pravastatin | 1992 |
45 trial(s) available for pravastatin and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Effects of Xuezhikang versus Pravastatin on Triglyceride Level in Patients with T2DM and Dyslipidemia: Study Protocol for a Multicenter Randomized Controlled Trial.
Topics: Atherosclerosis; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Lipids; Multicenter Studies as Topic; Pravastatin; Randomized Controlled Trials as Topic; Triglycerides | 2023 |
Effects of pravastatin on serum adiponectin levels in female patients with type 2 diabetes mellitus.
Topics: Adiponectin; Adult; Aged; Body Mass Index; Diabetes Complications; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Middle Aged; Pravastatin | 2013 |
Importance of high-density lipoprotein cholesterol control during pravastatin treatment in hypercholesterolemic Japanese with type 2 diabetes mellitus: a post hoc analysis of MEGA study.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin | 2013 |
Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia.
Topics: Angiotensin II Type 1 Receptor Blockers; Body Mass Index; Brachial Artery; C-Reactive Protein; Coronary Artery Disease; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Endothelium, Vascular; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Lipids; Male; Middle Aged; Phenotype; Pravastatin; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; China; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Rosuvastatin Calcium; Simvastatin | 2015 |
Effect of niacin on preβ-1 high-density lipoprotein levels in diabetes.
Topics: Aged; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; High-Density Lipoproteins, Pre-beta; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Niacin; Pravastatin; Retrospective Studies; Simvastatin | 2011 |
Progression of brain atrophy and cognitive decline in diabetes mellitus: a 3-year follow-up.
Topics: Aged; Aged, 80 and over; Atrophy; Brain; Cognition Disorders; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Hypoglycemic Agents; Insulin; Linear Models; Magnetic Resonance Imaging; Male; Neuropsychological Tests; Pravastatin | 2010 |
Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study.
Topics: Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Fenofibrate; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin | 2011 |
Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.
Topics: Aged; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 2012 |
Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy.
Topics: Aged; Albuminuria; Biomarkers; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Humans; Male; Pravastatin; Quinolines; Treatment Outcome | 2012 |
Effects of bezafibrate and pravastatin on remnant-like lipoprotein particles and lipoprotein subclasses in type 2 diabetes.
Topics: Aged; Aged, 80 and over; Bezafibrate; Cholesterol; Chromatography, High Pressure Liquid; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Triglycerides | 2003 |
Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.
Topics: Adult; Aged; Angina, Unstable; Anticholesteremic Agents; Blood Glucose; Cardiovascular Diseases; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, Type 2; Fasting; Female; Follow-Up Studies; Glucose Intolerance; Humans; Hyperlipidemias; Male; Middle Aged; Myocardial Infarction; Pravastatin; Risk Factors; Stroke; Treatment Outcome | 2003 |
Anti-inflammatory and anticoagulant effects of pravastatin in patients with type 2 diabetes.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Lipids; Male; Middle Aged; Netherlands; Pravastatin | 2004 |
Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
Topics: Aged; Arteriosclerosis; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Logistic Models; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2004 |
Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis; Biomarkers; C-Reactive Protein; Chemokine CCL2; Cholesterol; Comorbidity; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Imidazoles; Intercellular Adhesion Molecule-1; Interleukin-6; Lipids; Male; Middle Aged; Olmesartan Medoxomil; Pravastatin; Prospective Studies; Receptor, Angiotensin, Type 1; Tetrazoles; Treatment Outcome; Tumor Necrosis Factor-alpha; Vasculitis | 2004 |
Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoprotein Lipase; Middle Aged; Pravastatin; Pyrroles | 2004 |
Pravastatin reduces fibrinogen receptor gpIIIa on platelet-derived microparticles in patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Platelets; Cholesterol; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Humans; Integrin beta3; Macromolecular Substances; Male; Middle Aged; Platelet Activation; Pravastatin | 2005 |
HMG-CoA reductase inhibitors suppress the development and progression of carotid artery intimal-medial thickening in hypercholesterolemic type 2 diabetic patients.
Topics: Aged; Carotid Artery, Common; Cholesterol; Diabetes Mellitus, Type 2; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Simvastatin; Tunica Intima; Tunica Media | 2005 |
Effect of pravastatin in people with diabetes and chronic kidney disease.
Topics: Adult; Age Distribution; Aged; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Prevalence; Probability; Prognosis; Renal Insufficiency, Chronic; Risk Assessment; Sex Distribution; Treatment Outcome | 2005 |
[Effect of n-3 polyunsaturated fatty acids on plasma lipid, LDL lipoperoxidation, homocysteine and inflammation indicators in diabetic dyslipidemia treated with statin + fibrate combination].
Topics: Adult; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Fenofibrate; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Inflammation Mediators; Lipid Peroxidation; Lipids; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Single-Blind Method | 2005 |
Does pravastatin increase chylomicron remnant catabolism in postmenopausal women with type 2 diabetes mellitus?
Topics: Aged; Anticholesteremic Agents; Apolipoprotein B-48; Apolipoproteins B; Breath Tests; Carbon Isotopes; Cholesterol; Cholesterol, LDL; Chylomicron Remnants; Chylomicrons; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Humans; Mass Spectrometry; Metabolic Clearance Rate; Middle Aged; Pravastatin; Triglycerides | 2005 |
Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Blood Glucose; Diabetes Mellitus, Type 2; Epichlorohydrin; Female; Glycated Hemoglobin; Hemoglobins; Humans; Hypercholesterolemia; Imidazoles; Insulin Resistance; Male; Middle Aged; Pravastatin; Resins, Synthetic | 2007 |
Preferable effect of pravastatin compared to atorvastatin on beta cell function in Japanese early-state type 2 diabetes with hypercholesterolemia.
Topics: Atorvastatin; Cross-Over Studies; Diabetes Mellitus, Type 2; Glucose Intolerance; Glucose Tolerance Test; Heptanoic Acids; Humans; Hypercholesterolemia; Insulin-Secreting Cells; Japan; Patient Compliance; Pravastatin; Pyrroles | 2007 |
PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Myocardial Infarction; Pioglitazone; Pravastatin; Risk Factors; Simvastatin; Thiazolidinediones; Treatment Outcome; Triglycerides | 2007 |
Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Postmenopause; Pravastatin; Treatment Outcome | 1995 |
Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients.
Topics: Adult; Aged; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Male; Middle Aged; Niacin; Pravastatin; Treatment Outcome; Triglycerides | 1994 |
Clinical evaluation of pravastatin in the treatment of type II hyperlipidemia in patients with non-insulin-dependent diabetes mellitus.
Topics: Administration, Oral; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pravastatin; Treatment Outcome | 1995 |
Clinical efficacy of pravastatin for hyperlipidemia in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoproteins; Apolipoproteins B; Apolipoproteins E; Cholesterol, HDL; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Pravastatin; Triglycerides | 1995 |
Effect of treatment with a hydroxymethylglutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM.
Topics: Adult; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins; Middle Aged; Phosphatidylcholine-Sterol O-Acyltransferase; Pravastatin | 1995 |
Long-term efficacy and tolerability of pravastatin in hypercholesterolemia in patients with non-insulin-dependent diabetes mellitus. Hyogo Pravastatin Study Group.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins B; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glycated Hemoglobin; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Time Factors; Triglycerides | 1995 |
Improvement of glucose tolerance by bezafibrate in non-obese patients with hyperlipidemia and impaired glucose tolerance.
Topics: Bezafibrate; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Follow-Up Studies; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypercholesterolemia; Hyperlipidemias; Insulin; Male; Middle Aged; Pravastatin | 1994 |
A multi-centre study of the efficacy and safety of pravastatin in hypercholesterolaemic patients with non-insulin-dependent diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Hypercholesterolemia; Lipids; Male; Middle Aged; Pravastatin | 1994 |
A multinational study of the effects of low-dose pravastatin in patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia. Pravastatin Multinational Study Group for Diabetes.
Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Triglycerides | 1994 |
Effects of inhibiting cholesterol absorption and synthesis on cholesterol and lipoprotein metabolism in hypercholesterolemic non-insulin-dependent diabetic men.
Topics: Absorption; Anticholesteremic Agents; Blood Specimen Collection; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Patient Selection; Pravastatin; Sitosterols; Triglycerides | 1996 |
Effect of pravastatin in treatment of hypercholesterolemia in non-insulin-dependent diabetes patients.
Topics: Aged; Anticholesteremic Agents; Diabetes Mellitus, Type 2; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prospective Studies; Treatment Outcome | 1997 |
Efficacy of low-dose pravastatin in patients with mild hyperlipidemia associated with type II diabetes mellitus.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hyperlipidemias; Male; Middle Aged; Placebos; Pravastatin; Triglycerides | 1997 |
Combination of low-dose niacin and pravastatin improves the lipid profile in diabetic patients without compromising glycemic control.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Glucose; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Inhibitors; Female; Fructosamine; Humans; Hypercholesterolemia; Lipoprotein(a); Male; Middle Aged; Niacin; Pravastatin; Prospective Studies | 1997 |
Pravastatin in diabetes-associated hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hypercholesterolemia; Lipid Metabolism; Lipids; Male; Middle Aged; Pravastatin; Time Factors | 1997 |
Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentrations in patients with hyperlipidemia.
Topics: Aged; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Fatty Acids, Unsaturated; Female; Glyburide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypoglycemic Agents; Male; Middle Aged; Pravastatin; Simvastatin; Triglycerides | 1998 |
Effects of cholesterol-lowering treatments on oxidative modification of plasma intermediate density lipoprotein plus low density lipoprotein fraction in Type 2 diabetic patients.
Topics: Anticholesteremic Agents; Apolipoproteins B; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Humans; Hypercholesterolemia; Lipid Peroxidation; Lipid Peroxides; Lipoproteins; Lipoproteins, IDL; Lipoproteins, LDL; Male; Middle Aged; Phospholipids; Pravastatin; Probucol; Regression Analysis; Smoking; Time Factors; Triglycerides | 1999 |
Effect of treatment with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on serum coenzyme Q10 in diabetic patients.
Topics: Adult; Anticholesteremic Agents; Antioxidants; Cholesterol; Chromatography, High Pressure Liquid; Coenzymes; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Simvastatin; Ubiquinone | 1999 |
Effect of pravastatin on erythrocyte rheological and biochemical properties in poorly controlled Type 2 diabetic patients.
Topics: Anticholesteremic Agents; Blood Pressure; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Double-Blind Method; Electrolytes; Erythrocyte Deformability; Erythrocyte Membrane; Erythrocytes; Female; Fructosamine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Phospholipids; Placebos; Pravastatin; Reference Values; Rheology | 1999 |
Lipid management in patients at moderate risk for coronary heart disease: insights from the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).
Topics: Age Factors; Aged; Anticholesteremic Agents; Coronary Artery Disease; Coronary Disease; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lovastatin; Male; Middle Aged; Military Personnel; Practice Guidelines as Topic; Pravastatin; Primary Prevention; Risk; Risk Factors; Sex Factors; Smoking; Texas; Treatment Outcome | 1999 |
Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin; Lovastatin; Male; Middle Aged; Placebos; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2000 |
A comparison of pravastatin and gemfibrozil in the treatment of dyslipoproteinemia in patients with non-insulin-dependent diabetes mellitus.
Topics: Aged; Apolipoproteins; Cholesterol, LDL; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Evaluation; Female; Follow-Up Studies; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Patient Compliance; Phenotype; Pravastatin; Treatment Outcome; Triglycerides | 2002 |
49 other study(ies) available for pravastatin and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.
Topics: Allosteric Site; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Dogs; Enzyme Activators; Glucokinase; Haplorhini; Hepatocytes; Humans; Hypoglycemic Agents; Imidazoles; In Vitro Techniques; Insulin-Secreting Cells; Male; Models, Molecular; Nicotinic Acids; Organic Anion Transporters; Protein Binding; Rats; Rats, Sprague-Dawley; Rats, Wistar; Stereoisomerism; Structure-Activity Relationship; Tissue Distribution | 2012 |
Combined Administration of Pravastatin and Metformin Attenuates Acute Radiation-Induced Intestinal Injury in Mouse and Minipig Models.
Topics: Animals; Diabetes Mellitus, Type 2; Intestinal Diseases; Intestines; Metformin; Mice; Pravastatin; Radiation Injuries; Swine; Swine, Miniature | 2022 |
Long-term outcomes of statin dose, class, and use intensity on primary prevention of cardiovascular mortality: a national T2DM cohort study.
Topics: Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Pravastatin; Primary Prevention; Rosuvastatin Calcium; Simvastatin | 2023 |
[Effect of Statins on Glycemic Status and Plasma Adiponectin Concentrations in Patients with Type 2 Diabetes Mellitus and Hypercholesterolemia].
Topics: Adiponectin; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Insulin Resistance; Male; Middle Aged; Molecular Weight; Pravastatin | 2019 |
Risk of incident diabetes among patients treated with statins: population based study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Odds Ratio; Ontario; Population Surveillance; Pravastatin; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2013 |
Aortic superoxide production at the early hyperglycemic stage in a rat type 2 diabetes model and the effects of pravastatin.
Topics: Animals; Aorta; Blood Glucose; Catalase; Coronary Disease; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Endothelium, Vascular; Enzyme Inhibitors; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nitric Oxide Synthase Type III; Pravastatin; Protein Kinase C; Rats, Long-Evans; Superoxides | 2014 |
Incidence of type 2 diabetes among patients exposed to the combination of pravastatin and paroxetine.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Cohort Studies; Databases, Factual; Diabetes Mellitus, Type 2; Drug Combinations; Endpoint Determination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Insurance, Health; Male; Middle Aged; Paroxetine; Pravastatin; Retrospective Studies; Risk Assessment; Young Adult | 2015 |
Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus.
Topics: Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Drug Evaluation; Glucose Intolerance; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Quinolines; Retrospective Studies | 2008 |
Improvement of glucose intolerance by combination of pravastatin and olmesartan in type II diabetic KK-A(y) mice.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antimetabolites; Antioxidants; Blood Glucose; Cyclic N-Oxides; Deoxyglucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucose Intolerance; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Insulin; Male; Mice; Mice, Inbred C57BL; Mice, Inbred Strains; Oxidative Stress; Pravastatin; Spin Labels; Tetrazoles | 2009 |
Characteristic changes in coronary artery at the early hyperglycaemic stage in a rat type 2 diabetes model and the effects of pravastatin.
Topics: Animals; Coronary Vessels; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Male; Nitric Oxide Synthase Type III; Pravastatin; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Superoxides | 2009 |
Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Glucose-lowering effect of colestimide is associated with baseline HbA1c in type 2 diabetic patients with hypercholesterolemia.
Topics: Aged; Atorvastatin; Blood Glucose; Comorbidity; Diabetes Mellitus, Type 2; Epichlorohydrin; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hypercholesterolemia; Hypoglycemic Agents; Imidazoles; Lipids; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyrroles; Quinolines; Resins, Synthetic; Retrospective Studies; Treatment Outcome | 2011 |
Pravastatin normalizes endothelium-derived contracting factor-mediated response via suppression of Rho-kinase signalling in mesenteric artery from aged type 2 diabetic rat.
Topics: Aging; Animals; Diabetes Mellitus, Type 2; Endothelium, Vascular; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mesenteric Arteries; Pravastatin; Rats; Rats, Inbred OLETF; rho-Associated Kinases; Signal Transduction | 2012 |
Pravastatin normalizes ET-1-induced contraction in the aorta of type 2 diabetic OLETF rats by suppressing the KSR1/ERK complex.
Topics: Animals; Aorta, Thoracic; Aortic Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelin-1; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Pravastatin; Protein Kinases; Protein Phosphatase 2; Rats; Rats, Inbred OLETF; Signal Transduction; src-Family Kinases; Time Factors; Vasoconstriction; Vasoconstrictor Agents | 2012 |
The enigma of adiponectin.
Topics: Adiponectin; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin | 2013 |
[Statin treatment in type 2 diabetes. Is it a must today?].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Insulin Resistance; Life Style; Middle Aged; Placebos; Pravastatin; Primary Prevention; Risk Factors; Simvastatin | 2003 |
Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes.
Topics: Atorvastatin; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Sensitivity and Specificity; Simvastatin; United States | 2003 |
Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model.
Topics: Animals; Blood Glucose; Chemokine CCL2; Cholesterol; Diabetes Mellitus, Type 2; Disease Models, Animal; DNA Primers; Glucose Tolerance Test; Hydroxymethylglutaryl CoA Reductases; Immunohistochemistry; Insulin; Leptin; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Pravastatin; Rats; Rats, Inbred OLETF; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transforming Growth Factor beta; Transforming Growth Factor beta1; Triglycerides; Tumor Necrosis Factor-alpha; Ventricular Remodeling | 2004 |
Effects of a statin group drug, pravastatin, on the insulin resistance in patients with metabolic syndrome.
Topics: Diabetes Mellitus, Type 2; Female; Humans; Insulin Resistance; Metabolic Syndrome; Middle Aged; Pravastatin | 2004 |
Anti-oxidative effect of fluvastatin in hyperlipidemic type 2 diabetic patients.
Topics: Aged; Antioxidants; Cholestenes; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Erythrocyte Membrane; Fatty Acids, Monounsaturated; Female; Fluvastatin; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypoglycemic Agents; Indoles; Male; Middle Aged; Oxidative Stress; Pravastatin; Prospective Studies; Simvastatin; Thiobarbituric Acid Reactive Substances | 2005 |
Acute onset and worsening of diabetes concurrent with administration of statins.
Topics: Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Pyrroles | 2005 |
Protective role of pravastatin in the pathogenesis of the metabolic syndrome.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Humans; Insulin Resistance; Male; Metabolic Syndrome; Models, Biological; Models, Theoretical; Obesity; Pravastatin | 2006 |
Pravastatin activates platelet nitric oxide synthase (NOS) in patients with type 2 diabetes mellitus and NOS activation is accompanied by serine phosphorylation.
Topics: Blood Platelets; Diabetes Mellitus, Type 2; Enzyme Activation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Phosphorylation; Pravastatin; Serine | 2005 |
Statins for high-risk patients without heart disease or high cholesterol.
Topics: Atorvastatin; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Pravastatin; Pyrroles; Simvastatin; Stroke | 2006 |
Influences of statins on glucose tolerance in patients with type 2 diabetes mellitus.
Topics: Aged; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glucose Tolerance Test; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypoglycemic Agents; Male; Middle Aged; Pravastatin; Pyrroles; Retrospective Studies | 2006 |
Vasoactive drugs enhance pancreatic islet blood flow, augment insulin secretion and improve glucose tolerance in female rats.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Biphenyl Compounds; Blood Glucose; Captopril; Diabetes Mellitus, Type 2; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Irbesartan; Islets of Langerhans; Pancreas; Pravastatin; Rats; Rats, Wistar; Regional Blood Flow; Sex Factors; Tetrazoles; Vasodilator Agents | 2007 |
Are statins analogues of vitamin D?
Topics: Anticholesteremic Agents; C-Reactive Protein; Diabetes Mellitus, Type 2; Humans; Insulin; Insulin Secretion; Pravastatin; Vitamin D | 2006 |
Multitherapy for diabetes.
Topics: Bezafibrate; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Humans; Hypolipidemic Agents; Pravastatin | 2006 |
Differential impact of atorvastatin vs pravastatin on progressive insulin resistance and left ventricular diastolic dysfunction in a rat model of type II diabetes.
Topics: Adiponectin; Adipose Tissue; Animals; Anticholesteremic Agents; Atorvastatin; Chemokine CCL2; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression Regulation; Glucose; Heptanoic Acids; Hypertriglyceridemia; Insulin Resistance; Leptin; Myocardium; Nitric Oxide; Nitric Oxide Synthase Type III; Pravastatin; Pyrroles; Rats; Rats, Long-Evans; Rats, Mutant Strains; RNA, Messenger; Transforming Growth Factor beta1; Ventricular Dysfunction, Left | 2007 |
The effects of statin and fibrate on lowering small dense LDL- cholesterol in hyperlipidemic patients with type 2 diabetes.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Triglycerides | 2007 |
Effects of long-term pravastatin treatment on serum and urinary monocyte chemoattractant protein-1 levels and renal function in type 2 diabetic patients with normoalbuminuria.
Topics: Aged; Albuminuria; Chemokine CCL2; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney; Male; Middle Aged; Pravastatin | 2007 |
Gender-specific regulation of pancreatic islet blood flow, insulin levels and glycaemia in spontaneously diabetic Goto-Kakizaki rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Captopril; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Irbesartan; Islets of Langerhans; Male; Pravastatin; Rats; Rats, Mutant Strains; Regional Blood Flow; Sex Factors; Tetrazoles | 2008 |
Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study.
Topics: Anticholesteremic Agents; Apolipoproteins E; Cholesterol, LDL; Cohort Studies; Diabetes Mellitus, Type 2; Fatty Acids, Monounsaturated; Female; Fluvastatin; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Longitudinal Studies; Male; Middle Aged; Pravastatin; Pyridines; Retrospective Studies; Scotland; Simvastatin; Treatment Outcome | 2008 |
Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Diabetes Mellitus, Type 2; Female; Geriatrics; Humans; Male; Metabolic Syndrome; Middle Aged; Multicenter Studies as Topic; Pravastatin; Predictive Value of Tests; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors | 2008 |
Pravastatin-associated myopathy. Report of a case.
Topics: Acute Disease; Aged; Biopsy; Diabetes Mellitus, Type 2; Humans; Hypercholesterolemia; Hypertension; Male; Muscle, Skeletal; Muscular Diseases; Myositis; Pravastatin | 1995 |
Apolipoprotein E polymorphism affects the response to pravastatin on plasma apolipoproteins in diabetic patients.
Topics: Adult; Aged; Alleles; Apolipoproteins; Apolipoproteins E; Biomarkers; Diabetes Mellitus, Type 2; Diet, Diabetic; Female; Gene Frequency; Humans; Hypercholesterolemia; Hypoglycemic Agents; Insulin; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Pravastatin | 1993 |
Marked decrease in serum HDL cholesterol levels by combined probucol-pravastatin treatment in hypercholesterolemic NIDDM patients.
Topics: Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Middle Aged; Pravastatin; Probucol; Triglycerides | 1993 |
Effect of pravastatin on plasma ketone bodies in diabetics with hypercholesterolemia.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Aged; Aged, 80 and over; Body Mass Index; Cholesterol; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Humans; Hydroxybutyrates; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Ketone Bodies; Male; Middle Aged; Pravastatin | 1998 |
[Treatment with pravastatin of dyslipidemia associated with diabetic nephropathy].
Topics: Anticholesteremic Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hyperlipidemias; Male; Middle Aged; Pravastatin | 1998 |
Hepatic failure in a patient taking rosiglitazone.
Topics: Aged; Combined Modality Therapy; Coronary Disease; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Ischemia; Liver; Liver Failure; Male; Monitoring, Physiologic; Pravastatin; Rosiglitazone; Thiazoles; Thiazolidinediones; Verapamil | 2000 |
Clinical trials and clinical practice--bridging the gaps in type 2 diabetes. An evidence-based approach to risk factor modification in type 2 diabetes.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Evidence-Based Medicine; Humans; Hypertension; Hypoglycemic Agents; Metformin; Myocardial Ischemia; Practice Guidelines as Topic; Pravastatin; Risk Factors | 2000 |
A case for lipid-lowering?
Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, Type 2; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Risk Factors; Triglycerides | 2000 |
Do interventions to reduce coronary heart disease reduce the incidence of type 2 diabetes? A possible role for inflammatory factors.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 2; Finland; Glucose Tolerance Test; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Incidence; Life Style; Male; Metformin; Pravastatin; Risk Factors; Scotland | 2001 |
Is pseudocholinesterase activity related to markers of triacylglycerol synthesis in Type II diabetes mellitus?
Topics: Aged; Anticholesteremic Agents; Apolipoproteins E; Bezafibrate; Biomarkers; Butyrylcholinesterase; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin; Linear Models; Male; Phenotype; Pravastatin; Triglycerides | 2001 |
Effect of bezafibrate or pravastatin on serum lipid levels and albuminuria in NIDDM patients.
Topics: Albuminuria; Apolipoprotein A-I; Apolipoprotein B-100; Apolipoproteins B; Bezafibrate; Blood Pressure; Case-Control Studies; Cholesterol; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Humans; Hypercholesterolemia; Hypolipidemic Agents; Insulin; Lipids; Male; Middle Aged; Pravastatin | 2000 |
Remarkably high prevalence of small dense low-density lipoprotein in Japanese men with coronary artery disease, irrespective of the presence of diabetes.
Topics: Aged; Apolipoprotein A-I; Apolipoproteins B; Blood Glucose; Body Mass Index; Coronary Artery Disease; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypolipidemic Agents; Japan; Lipoprotein(a); Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Prevalence; Simvastatin; Triglycerides | 2002 |
Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Antihypertensive Agents; Cholesterol; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Neuropathies; Disease Progression; Humans; Hypoglycemic Agents; Insulin; Markov Chains; Middle Aged; Pravastatin; Quality-Adjusted Life Years; Sulfonylurea Compounds; United States | 2002 |
Effect of pravastatin on serum lipids, apolipoproteins and lipoprotein (a) in patients with non-insulin dependent diabetes mellitus.
Topics: Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypoglycemic Agents; Lipids; Lipoprotein(a); Lipoproteins; Male; Pravastatin; Triglycerides | 1992 |
Long-term treatment of hypercholesterolemic non-insulin dependent diabetics (NIDDM) with pravastatin (CS-514).
Topics: Adult; Anticholesteremic Agents; Apolipoproteins; Blood Glucose; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Aged; Naphthalenes; Pravastatin; Time Factors | 1989 |